EC Number | Cloned (Comment) | Organism |
---|---|---|
2.4.1.244 | truncated form of the human enzyme is expressed in HEK293T cells as a soluble protein | Homo sapiens |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.4.1.244 | additional information | Homo sapiens | the enzyme could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans | ? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.4.1.244 | Homo sapiens | Q6L9W6 | - |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
2.4.1.244 | - |
Homo sapiens |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.4.1.244 | colon | highly expressed in | Homo sapiens | - |
2.4.1.244 | stomach | highly expressed in | Homo sapiens | - |
2.4.1.244 | testis | highly expressed in | Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.4.1.244 | additional information | the enzyme could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans | Homo sapiens | ? | - |
? | |
2.4.1.244 | additional information | the most efficient acceptor substrate in the N-glycans examined is a non-fucosylated bi-antennary one. The enzyme shows no activity towards chondroitin-related acceptors containing GlcUA as their non-reducing termini | Homo sapiens | ? | - |
? | |
2.4.1.244 | UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | 45% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + Gal-beta-(1,4)-GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
2.4.1.244 | UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | 51.7% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | - |
? | |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | 21.6% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | 5% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside | 87.1% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | Homo sapiens | UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside | - |
? | |
2.4.1.244 | UDP-GalNAc + GlcNAcbeta-O-benzyl | - |
Homo sapiens | UDP + GalNAc-beta-(1,4)-GlcNAcbeta-O-benzyl | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.4.1.244 | beta1,4-N-acetylgalactosaminyltransferase III | - |
Homo sapiens |
2.4.1.244 | beta1,4-N-acetylgalactosaminyltransferase IV | - |
Homo sapiens |
2.4.1.244 | beta1,4-N-acetylgalactosaminyltransferase-III | - |
Homo sapiens |
2.4.1.244 | beta4GalNAc-T3 | - |
Homo sapiens |
2.4.1.244 | beta4GalNAc-T4 | - |
Homo sapiens |
2.4.1.244 | N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 2 | - |
Homo sapiens |